Accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) treated with STI-571 (Gleevec): Peripheral blood (PB) and bone marrow (BM) findings

被引：0
|
作者：
Frater, JL [1 ]
Tallman, MS [1 ]
Variakojis, D [1 ]
Boehlke, L [1 ]
Peterson, LC [1 ]
机构：
[1] Northwestern Univ, Sch Med, Chicago, IL USA
来源：
LABORATORY INVESTIGATION | 2002年 / 82卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1006
引用
收藏
页码：241A / 241A
页数：1
相关论文
共 50 条
  • [41] A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
    Giles, F. J.
    le Coutre, P.
    Bhalla, K.
    Rosti, G.
    Ossenkoppele, G.
    Alimena, G.
    Weitzman, A.
    Zheng, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors
    Shulman, David S.
    Lee, Michelle A.
    Lehmann, Leslie E.
    Margossian, Steven P.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (08) : 610 - 614
  • [43] RESOLUTION OF ABNORMAL CHROMOSOMES FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA IN ACCELERATED PHASE OR BLAST CRISIS
    MCGLAVE, PB
    MILLER, WJ
    HURD, DD
    ARTHUR, DC
    KIM, T
    CLINICAL RESEARCH, 1981, 29 (02): : A340 - A340
  • [44] Phase II study of decitabine in combination with imatinib mesylate in patients with accelerated (AP) or blastic phase (BP) of chronic myeloid leukemia (CML).
    Oki, Y
    Kantarjian, HM
    O'Brien, S
    Verstovsek, S
    Gharibyan, V
    Cortes, J
    Morris, GM
    Garcia-Manero, G
    Issa, JP
    BLOOD, 2005, 106 (11) : 320A - 320A
  • [45] Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study
    le Coutre, P.
    Giles, F. J.
    Apperley, J.
    Ottmann, O. G.
    Larson, R. A.
    Haque, A.
    Gallagher, N.
    Rosti, G.
    Cortes, J. E.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] MOLECULAR MONITORING OF BCR/ABL FUSION GENE IN CHRONIC MYELOGENOUS LEUKEMIA (CML) - PERIPHERAL-BLOOD (PB) ANALYSIS IS COMPARABLE TO A BONE-MARROW (BM) EXAMINATION (CALGB-8761)
    STOCK, W
    WESTBROOK, CA
    PETERSON, B
    SZATROWSKI, TP
    SILVER, RT
    SCHIFFER, CA
    BLOOMFIELD, CD
    BLOOD, 1993, 82 (10) : A331 - A331
  • [47] Identification of bone marrow morphologic features which correlate with the presence of the Philadelphila chromosome in STI571-treated, chronic phase chronic myeloid leukemia.
    Schlette, EJ
    Onciu, M
    Giles, F
    Kantarjian, HM
    Lai, R
    BLOOD, 2001, 98 (11) : 267B - 267B
  • [48] Pharmacokinetic analysis of nilotinib in Chinese chronic myelogenous leukemia (CML) patients (pts) with imatinib-resistant or-intolerant disease in blast crisis (BC), accelerated phase (AP) or chronic phase (CP)
    Zhou, L.
    Hu, P.
    Meng, F.
    Wang, J.
    Wang, C.
    Hu, Z.
    Shen, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Survival advantage for patients (pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) treated with imatinib.
    Cortes, J
    Talpaz, M
    O'Brien, S
    Garcia-Manero, G
    Ravandi-Kashami, F
    Giles, F
    Faderl, S
    Wierda, W
    Shan, JQ
    Rios, MB
    Kantaijian, H
    BLOOD, 2004, 104 (11) : 287A - 288A
  • [50] Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia
    Kantarjian, HM
    Talpaz, M
    Cortes, J
    O'Brien, S
    Faderl, S
    Thomas, D
    Giles, F
    Rios, MB
    Shan, JQ
    Arlinghaus, R
    CLINICAL CANCER RESEARCH, 2003, 9 (01) : 160 - 166
12345